What's in Qilu Pharmaceutical Co., Ltd.'s pipeline?

Qilu Pharmaceutical Co., Ltd. has 113 drugs in our index: 7 marketed, 0 filed, 41 in Phase 3, 12 in Phase 2, 53 in Phase 1.

Which companies overlap with Qilu Pharmaceutical Co., Ltd.'s portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Pfizer, AstraZeneca, Jiangsu HengRui Medicine Co., Ltd., Eli Lilly and Company.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/qilu-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Qilu Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Qilu Pharmaceutical Co., Ltd. pipeline: 7 marketed, 0 filed, 41 Phase 3, 12 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

7 marketed 0 filed 41 Phase 3 12 Phase 2 53 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Tafamidis Meglumine Soft Capsules	Tafamidis Meglumine Soft Capsules	marketed	Transthyretin stabilizer	Transthyretin (TTR)	Rare disease / Neurology / Cardiology
DARZALEX FASPRO®	DARZALEX FASPRO®	marketed
QL0605(PEG-rhG-CSF)	QL0605(PEG-rhG-CSF)	marketed	Pegylated G-CSF (granulocyte colony-stimulating factor)	G-CSF receptor (GCSFR)	Oncology
Xiidra	Xiidra	marketed		Integrin alpha-L/beta-2, Intercellular adhesion molecule 1	Other
Tezspire	Tezspire	marketed		Thymic stromal lymphopoietin	Respiratory
Ceftazidime-avibactam	Ceftazidime-avibactam	marketed	Beta-lactam/beta-lactamase inhibitor combination	Penicillin-binding proteins (PBPs); serine beta-lactamases	Infectious Disease
Prolia®	Prolia®	marketed
QL1604	QL1604	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
QL2108 injection	QL2108 injection	phase 3
Tilesizumab	Tilesizumab	phase 3			Other
QLS32015	QLS32015	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
WX-0593 Tablets	WX-0593 Tablets	phase 3	HIF-1α inhibitor	HIF-1α	Oncology

Therapeutic area mix

Diabetes · 11
Oncology · 7
unknown · 4
Other · 3
Immunology · 3
Infectious Disease · 2
Respiratory · 1
Neurology · 1
Endocrinology / Diabetes · 1
Hematology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 7 shared drug classes
Pfizer · 7 shared drug classes
AstraZeneca · 5 shared drug classes
Jiangsu HengRui Medicine Co., Ltd. · 4 shared drug classes
Eli Lilly and Company · 4 shared drug classes
Merck Sharp & Dohme LLC · 4 shared drug classes
Hoffmann-La Roche · 4 shared drug classes
Sanofi · 4 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Qilu Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Qilu Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/qilu-pharmaceutical-co-ltd. Accessed 2026-05-16.